par Renneson, J;Salio, M;Mazouz, N;Goldman, Michel
;Marchant, Arnaud
;Cerundolo, V
Référence Clinical and experimental immunology, 139, 3, page (468-475)
Publication Publié, 2005-03
;Marchant, Arnaud
;Cerundolo, VRéférence Clinical and experimental immunology, 139, 3, page (468-475)
Publication Publié, 2005-03
Article révisé par les pairs
| Titre: |
|
| Auteur: | Renneson, J; Salio, M; Mazouz, N; Goldman, Michel; Marchant, Arnaud; Cerundolo, V |
| Informations sur la publication: | Clinical and experimental immunology, 139, 3, page (468-475) |
| Statut de publication: | Publié, 2005-03 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| Mots-clés: | Cancer |
| Cytotoxic T cells | |
| Dendritic cells | |
| Vaccines | |
| MeSH keywords: | CD40 Ligand -- immunology |
| CD8-Positive T-Lymphocytes -- immunology | |
| Cancer Vaccines | |
| Cell Differentiation | |
| Cell Line, Tumor | |
| Dendritic Cells -- immunology | |
| Flow Cytometry | |
| Humans | |
| Interferon-beta -- immunology | |
| Interferon-gamma -- immunology | |
| Interleukin-3 -- immunology | |
| Interleukin-5 -- immunology | |
| Lymphocyte Activation | |
| Lymphoma -- immunology | |
| Lymphoma -- therapy | |
| T-Lymphocytes, Cytotoxic -- immunology | |
| Note générale: | Journal Article |
| Research Support, Non-U.S. Gov't | |
| FLWIN | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0009-9104 |
| info:doi/10.1111/j.1365-2249.2005.02700.x | |
| info:pii/CEI2700 | |
| info:scp/14744302052 | |
| info:pmid/15730392 | |
| PMC1809309 |



